Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
复制标题
DOI：
10.1111/bjh.13040
复制
发表时间：
2014-11
影响因子：
6.5
通讯作者：
Cairo MS
中科院分区：
文献类型：
--
作者：
Goldman S;Smith L;Galardy P;Perkins SL;Frazer JK;Sanger W;Anderson JR;Gross TG;Weinstein H;Harrison L;Shiramizu B;Barth M;Cairo MS
儿童和青少年Burkitt淋巴瘤(BL)合并中枢神经系统(CNS)和骨髓受累，单用化疗预后较差。因此，我们在患有骨髓(≥25%的原始细胞)和/或中枢神经系统阳性的伯基特淋巴瘤的儿童和青少年中，研究了利妥昔单抗(375 mg/m2)和我们之前报道的法国-美国-英国(FAB)淋巴管Malins de Burkitt(LMB)96试验的标准化疗组合。同时还进行了中心病理学和细胞遗传学特征的研究。Burkitt组织学可评价的患者40例(白血病25例，中枢神经系统病±白血病15例)。化疗免疫方案耐受性良好。联合化疗和利妥昔单抗诱导周期中III/IV级粘膜炎的发生率分别为31%和26%。3年无事件生存率(EFS)/总生存率(OS)在整个队列中为90%(95%可信区间，76~96%)，在中枢神经系统疾病患者中为93%(95%可信区间，61~99%)。根据这项试验的结果，目前正在进行一项针对高危患者的FAB/LMB 96化疗±利妥昔单抗的国际随机研究。
Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m2) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76–96%) in the entire cohort and 93% (95% CI, 61–99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation.
登录
查看更多内容
影响因子：
45.3
作者：
Meinhardt, Andrea;Burkhardt, Birgit;Reiter, Alfred
通讯作者：
Reiter, Alfred
影响因子：
11.4
作者：
Poirel, H. A.;Cairo, M. S.;Patte, C.
通讯作者：
Patte, C.
影响因子：
51.1
作者：
Pfreundschuh, Michael;Trumper, Lorenz;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
50.5
作者：
Barnes, J. A.;LaCasce, A. S.;Abramson, J. S.
通讯作者：
Abramson, J. S.
影响因子：
20.3
作者：
Rubenstein, JL;Combs, D;Shuman, MA
通讯作者：
Shuman, MA